Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer-Reference-Cited by-同舟云学术

Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer

Published:2014-06-11 Issue:3 Volume:24 Page:253-261
ISSN:1057-9249
Container-title:Psycho-Oncology
language:en
Short-container-title:Psycho-Oncology

Author:

Tate Wendy R.¹²,Skrepnek Grant H.³⁴

Affiliation:

1. College of Pharmacy; The University of Arizona; Tucson AZ USA

2. The University of Arizona Cancer Center; The University of Arizona; Tucson AZ USA

3. College of Pharmacy; The University of Oklahoma Health Sciences Center; Oklahoma City OK USA

4. Peggy and Charles Stephenson Cancer Center; The University of Oklahoma Health Sciences Center; Oklahoma City OK USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Oncology,Experimental and Cognitive Psychology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pon.3595/fullpdf

Reference62 articles.

1. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis;Goldhirsch;J Clin Oncol,1989

2. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer;Gelber;J Clin Oncol,1986

3. Comparing treatments using quality-adjusted survival-the Q-TWiST method;Gelber;Am Stat,1995

4. Quality adjusted survival analysis;Glasziou;Stat Med,1990

5. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'etude les lymphomes de l'adulte (GELA);Mounier;Blood,2000

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial;Lung Cancer;2023-11

2. Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1;European Journal of Cancer;2022-12

3. Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial;Clinical Breast Cancer;2021-12

4. Literatur;ELSEVIER ESSENTIALS Onkologie;2021

5. Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients;South Asian Journal of Cancer;2018-10